Actively Recruiting
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Led by Ruijin Hospital · Updated on 2026-01-02
30
Participants Needed
1
Research Sites
118 weeks
Total Duration
On this page
Sponsors
R
Ruijin Hospital
Lead Sponsor
J
Jiangsu HengRui Medicine Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the safety and efficacy of HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
CONDITIONS
Official Title
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years, male or female
- Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas with at least one measurable lesion
- Imaging evaluation meeting NCCN guidelines for resectable or borderline resectable pancreatic cancer
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy of at least 12 weeks
- Adequate bone marrow and organ function
- Negative pregnancy test for females of childbearing age within one week before study start and agreement to use effective contraception during and after the study
- Male participants with partners of childbearing potential agree to use effective contraception during and after the study
- Willingness to participate and signed informed consent
You will not qualify if you...
- Prior anti-tumor therapy received
- Presence of distant metastatic lesions
- Known allergy to study drugs or their components
- Previous or concurrent other malignant tumors
- Participation in another clinical trial within 4 weeks prior to first dose
- Receipt of live or attenuated vaccines within 4 weeks prior to first dose
- Previous allogeneic stem cell or organ transplantation
- Severe cardiovascular conditions including thromboembolism, NYHA class 2 or higher heart failure, or significant arrhythmias requiring treatment
- Interstitial lung disease, non-infectious pneumonia, or severe uncontrolled illness
- Acute infections or recent major surgery within 28 days or not fully recovered
- Congenital or acquired immunodeficiencies including HIV, active hepatitis B or C, or co-infection
- Active or history of autoimmune diseases except resolved childhood asthma without intervention
- Systemic corticosteroid or immunosuppressive treatment within 2 weeks prior to first dose except low-dose inhaled/topical steroids or adrenal hormone replacement
- Other conditions deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, China
Actively Recruiting
Research Team
B
Baiyong shen, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here